Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sinovac Biotech Ltd.    SVA   AGP8696W1045

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac Biotech : China's Sinovac to double annual COVID-19 vaccine capacity to 1 billion doses

01/13/2021 | 04:42am EST
Outbreak of the coronavirus disease (COVID-19), in Sao Paulo

BEIJING (Reuters) - A unit of Sinovac Biotech could double annual production capacity of its CoronaVac COVID-19 vaccine to 1 billion doses by February, the group's chairman said on Wednesday.

More than 7 million doses of CoronaVac vaccine, one of the three China has included in its emergency vaccination programme, have so far been supplied to regions including the city of Beijing and Guangdong province, Sinovac Biotech Chairman Yin Weidong told a news conference.

While the first phase of Sinovac Life Sciences' existing production line can make 500 million CoronaVac doses in one year, another with annual capacity of 500 million doses could become operational by February, Yin said.

Researchers in Brazil on Tuesday released new efficacy data for the vaccine, for which there have been varying rates of success from trial sites in three countries.

Trials in different countries are designed differently, but the CoronaVac doses being tested came from the same batch, Yin said.

"These Phase III clinical trial results are sufficient to prove that CoronaVac vaccine's safety and effectiveness are good around the world," Yin said.

China has given over 10 million COVID-19 doses so far, Wang Bin, an official of National Health Commission, told reporters.

As clinical trial data and vaccine supply increases, the country will gradually include those older than 60 to its vaccination scheme, which is currently focused on people aged between 18-59 in priority groups of higher infection risk, Wang said, without giving a clear timeline.

(Reporting by Roxanne Liu and Yew Lun Tian; Editing by David Goodman and Louise Heavens)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
EURO / BRAZILIAN REAL (EUR/BRL) 2.24% 6.6542 Delayed Quote.2.58%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.-6.77%
All news about SINOVAC BIOTECH LTD.
01/22WHO to consider two Chinese COVID-19 vaccines next week
RE
01/20McKesson to replace some Moderna COVID-19 vaccines due to low temperature
RE
01/20WHO plans slew of COVID-19 vaccine approvals for global rollout
RE
01/20Three COVID-19 vaccines under final review for emergency use - WHO
RE
01/20WHO plans slew of COVID-19 vaccine approvals for global rollout - document
RE
01/20China's COVID-19 vaccine makers apply to join COVAX scheme
RE
01/20COVID-19 vaccine shots add to confusion over China's tests for travellers
RE
01/19Brazil battles Chinese red tape to get active vaccine ingredients
RE
01/19Philippines to buy 20 million Moderna vaccine doses as COVID-19 cases rise
RE
01/18Philippines to buy 20 mln doses of Moderna's COVID-19 vaccine
RE
More news
Financials (USD)
Sales 2019 246 M - -
Net income 2019 44,9 M - -
Net cash 2019 183 M - -
P/E ratio 2019 17,8x
Yield 2019 -
Capitalization 640 M 640 M -
EV / Sales 2018 1,38x
EV / Sales 2019 1,86x
Nbr of Employees 910
Free-Float 34,7%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang Chief Financial Officer & Vice President
Qiang Gao Vice President-Research & Development
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SINOVAC BIOTECH LTD.-6.77%640
CSL LIMITED-3.03%96 409
SAMSUNG BIOLOGICS CO.,LTD.-3.87%47 496
BIOGEN INC.10.04%41 462
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.10.88%40 484
ALEXION PHARMACEUTICALS, INC.1.04%34 956